Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis? Yamamoto T. Aliment Pharmacol Ther 2023;58:546-547.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yamamoto T. Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis? Aliment Pharmacol Ther 2023;58:546-547.
PMID: 37559519